Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: Jun 6th, 3:35 PM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | 25.15 - 33.59 |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
Intelligent Bio Solutions Inc. (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25 as U.S. Expansion Advances
Intelligent Bio Solutions (NASDAQ: INBS), a medical technology company specializing in rapid, non-invasive testing solutions, recently attended the RISE25 conference to demonstrate its portable Intelligent Fingerprint Drug Screening System, continuing its push into the U.S. market for rapid, non-invasive screening technologies ( https://ibn.fm/1JSTS ).
Via Investor Brand Network · June 6, 2025
Soligenix Inc. (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL
Cutaneous T-cell lymphoma (“CTCL”) is a rare and debilitating form of non-Hodgkin’s lymphoma that primarily affects the skin, posing both physical and emotional challenges for those diagnosed. With limited treatment options available and no definitive cure, the need for innovative, safe and effective therapies is urgent. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is focused on developing and commercializing products to treat rare diseases. At the forefront of Soligenix’s pipeline is HyBryte(TM), a novel therapy aimed at treating early-stage CTCL.
Via Investor Brand Network · June 6, 2025
More American Doctors are Relocating to Canada, Citing Federal Government Issues
As U.S. news outlets focus on the economic turmoil triggered by tariffs, another story is quietly developing. More doctors trained and working in the U.S. are relocating to Canada and the reasons they are giving rotate around the actions and policies of the Trump administration.
Via Investor Brand Network · June 6, 2025
BioMedNewsBreaks — FDA Accelerates Launch of AI Tool Elsa, Raising Questions on Transparency and Oversight
The U.S. Food and Drug Administration (“FDA”) has fast-tracked the rollout of its AI tool, Elsa, originally planned for June 30, with Commissioner Dr. Marty Makary touting the launch as both “ahead of schedule and under budget.” Elsa is already streamlining workflows across the agency, reducing multiday review tasks to minutes, and handling administrative functions such as safety profile assessments, label comparisons, and protocol reviews. The tool is housed in a secure GovCloud environment and was not trained on industry-submitted data, according to Makary.
Via Investor Brand Network · June 6, 2025
Via The Motley Fool · June 5, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Host Webcast With CEO to Share Updates on Alzheimer’s and Parkinson’s Programs
Annovis Bio (NYSE: ANVS) announced it will host a live webcast on June 24, 2025, at 4:30 PM EDT, featuring President and CEO Maria Maccecchini, Ph.D. The event will provide updates on the company’s pivotal Phase 3 trial for early Alzheimer’s disease, recent FDA feedback on its Parkinson’s disease program, and other key initiatives. The webcast will include a brief presentation followed by a live Q&A session open to shareholders, patients, and other stakeholders.
Via Investor Brand Network · June 5, 2025
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Receives Italian Clearance for Option to Acquire Biotech Firm Pincell
Scinai Immunotherapeutics (NASDAQ: SCNI) announced it has received regulatory clearance under Italy’s Golden Power regulation to proceed with its option to acquire 100% of Pincell S.r.l., an Italian biotech company. The approval, issued by Italy’s Coordination Group and Ministry of Health, supports Scinai’s strategic move to expand its inflammation and immunology pipeline. Pincell’s lead asset, PC111—a monoclonal antibody targeting the Fas/FasL pathway—holds Orphan Drug Designation in Pemphigus and is being developed for severe skin disorders. The acquisition remains subject to final conditions, including a €12 million grant decision expected later this summer.
Via Investor Brand Network · June 5, 2025
Therapeutic Target Shows Promise in Preventing Cancer Resulting from Chronic Gut Inflammation
When inflammatory bowel disease becomes chronic, it is difficult to treat and comes with the likelihood of various complications, such as the onset of bowel cancer. This disease in its chronic form manifests as Crohn’s disease or ulcerative colitis. These diseases particularly impact young people. Early diagnosis followed by treatment is crucial in these cases.
Via Investor Brand Network · June 5, 2025
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit
CNS Pharmaceuticals (NASDAQ: CNSP) announced that Chief Medical Officer Sandra Silberman, M.D., Ph.D., will present at the Brain Tumor Biotech Summit hosted by Lenox Hill Hospital’s Department of Neurosurgery on June 5, 2025. Her presentation, titled “The Future and Promise of TPI 287,” will highlight CNS’s brain-penetrating taxane candidate, which has shown efficacy in glioblastoma patients, including 3 complete and 9 partial responses in a Phase 1 trial. TPI 287, which has FDA Orphan Drug Designation for gliomas, pediatric neuroblastoma, and progressive supranuclear palsy, may offer a breakthrough in treating CNS tumors by effectively crossing the blood-brain barrier.
Via Investor Brand Network · June 5, 2025
Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology
As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming to transform how opioid-based therapies are administered and protected against misuse, using its proprietary Aversa technology to set a new standard for transdermal pain and addiction treatments.
Via Investor Brand Network · June 5, 2025
Nutriband Inc. (NASDAQ: NTRB): A Relentless Mission Rooted in Purpose, Innovation, and Shareholder Value
Serguei Melnik, Founder and President of Nutriband (NASDAQ: NTRB), recently joined The Smart Money Circle Show , where he pulled back the curtain on his no-nonsense approach to biotech entrepreneurship. His grounded tone and unwavering focus on long-term value stand in stark contrast to the conventional biotech playbook.
Via Investor Brand Network · June 4, 2025
Study Finds That Kids, Young People Wait Longer to Receive a Cancer Diagnosis
A recent study conducted by experts based at University of Nottingham in the UK has revealed that young individuals afflicted by certain kinds of cancer like bone malignancies take longer before being diagnosed .
Via Investor Brand Network · June 3, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Conference
Nutriband (NASDAQ: NTRB) announced that CEO Gareth Sheridan will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Thursday, June 5 at 4 p.m. ET. The session will feature a fireside-style Q&A open to live audience questions, with 1×1 meetings available for qualified investors. A webcast of the presentation will be accessible post-event on Nutriband’s website and Channelchek.com, where it will remain archived for 90 days.
Via Investor Brand Network · June 3, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Posts Record Q1 Revenue, Advances AVERSA Fentanyl Development
Nutriband (NASDAQ: NTRB) reported first-quarter revenue of $667,000, a 63% year-over-year increase driven by expanded kinesiology tape production through its Pocono Pharma subsidiary and growing retail presence at Target, Walmart, Walgreens, and CVS. The company continues to prioritize shareholder value by scaling Pocono’s output through penetration pricing strategies while advancing development of AVERSA Fentanyl, an abuse-deterrent transdermal opioid patch. A newly formalized partnership with Kindeva Drug Delivery will support shared development costs in exchange for milestone payments as AVERSA moves toward regulatory approval. The product is projected to reach peak U.S. sales of $80 million to $200 million annually.
Via Investor Brand Network · June 2, 2025
Solutions to serious problems are always marketable, even if the overall economy isn't quite firing on all cylinders.
Via The Motley Fool · May 31, 2025
Riding Russia’s Edge: Ksyusha’s Pro Training for the EXTREME Adventure
Before embarking on the thrilling EXTREME Russia expedition with QJMOTOR and Benelli, Ksyusha, the adventurous rider, sought expert guidance to ensure a safe and exhilarating journey. She received a meticulous pro briefing from Evgeny Pyatigorsky, the esteemed Chief Instructor of BMW Motorrad Russia and a seasoned expert in the grueling Silk Way Rally. With decades of experience navigating extreme terrains and a reputation for training elite riders, Pyatigorsky’s insights were invaluable in preparing Ksyusha for the challenges ahead.
Via AB Newswire · May 30, 2025
Study Links Autism to Increased Risk of Developing Parkinson’s Disease
A recently conducted study by a team at Karolinska Institutet in Sweden has established a link between a diagnosis of autism spectrum disorder (ASD) to a heightened risk of Parkinson’s disease (PD). The research appeared in the journal JAMA Neurology . The research team believes the two conditions may share a number of underlying biological mechanisms.
Via Investor Brand Network · May 30, 2025
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Reports Q1 Revenue Growth Driven by CDMO Contracts, Net Loss Narrows
Scinai Immunotherapeutics (NASDAQ: SCNI) reported first quarter 2025 financial results, posting $586K in revenue, up from zero in the prior-year period, reflecting continued expansion of its CDMO business. R&D expenses declined to $1.3M from $1.6M, while marketing, general and administrative costs held steady at $500K. The company recorded a $1.6M net loss, improving from a $2.2M loss in Q1 2024, aided by reduced R&D and financial expenses. Cash and equivalents totaled $1M at quarter-end, down from $2M a year earlier.
Via Investor Brand Network · May 30, 2025
Alzamend Neuro (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company tackling some of the most pressing neurological and psychiatric conditions of our time — including Alzheimer’s disease, Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). With a mission to “Make Alzheimer’s Just a Memory,” the Atlanta-based company is advancing a robust pipeline of therapies aimed at delivering long-overdue innovation in safety, efficacy, and tolerability. Rather than tweaking existing treatments, Alzamend is engineering bold new approaches that directly address the limitations of current standards of care.
Via Investor Brand Network · May 29, 2025
University of Houston Gets $3M to Establish Biomarker Core for Cancer Immunotherapy
Texas’ Cancer Prevention & Research Institute has awarded $3 million to the University of Houston to establish a biomarker core for cancer immunotherapy. The research institute has earned a reputation for funding research projects which are groundbreaking. The $3m is a fraction of its $93m total package earmarked for awarding grants to entities within the state.
Via Investor Brand Network · May 29, 2025
The automakers are hoping for a deal in June, a source told Reuters, while noting that it would rely on the companies pledging substantial investment in the U.S. to convince the administration.
Via Stocktwits · May 28, 2025
Gilston, QLD () May 28, 2025 -- Paradise Car Keys’s specialized services for luxury brands include EEPROM programming, ignition repairs, and advanced diagnostics.
Via Prodigy · May 28, 2025
House Approves Reconciliation Bill, Health Insurance and Medicaid to Be Impacted
On May 22, the U.S. House of Representatives approved the reconciliation bill for the 2025 budget with a one-vote difference between those in support of the bill and those opposed to it. The American Hospital Association says this legislation is going to have notable impacts upon healthcare insurance and Medicaid.
Via Investor Brand Network · May 28, 2025
BioMedNewsBreaks — TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Appoints RNAi Pioneer Phillip Zamore to Scientific Advisory Board
TransCode Therapeutics (NASDAQ: RNAZ), has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of Alnylam Pharmaceuticals, to its Scientific Advisory Board. Dr. Zamore, currently Chair of the RNA Therapeutics Institute at UMass Chan Medical School, is renowned for his foundational work in RNA biology and gene silencing mechanisms. His election to the National Academy of Sciences and other prestigious institutions underscores his impact on the field. TransCode leaders praised the addition as a strategic enhancement to the company’s RNA-targeted cancer therapy programs.
Via Investor Brand Network · May 28, 2025